SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________

FORM 8-K

__________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): ~~January~~August 181, 2022

CANNAGISTICS, INC.

(Exact name of registrant as specified in charter)

Delaware	000-55711	86-3911779
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

150 Motor Parkway, Suite 401 Hauppauge, NY	11788
150 Motor Parkway Suite 401 Hauppauge, NY	11788
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: 631-787-8455

2110 5th Avenue

Ronkonkoma, NY

631-676-7230

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13ed-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange. ~~[ ]~~

~~Item~~SECTION ~~1.01~~5 ~~Entry~~– ~~into~~CORPORATE aGOVERNANCE ~~Material~~AND ~~Definitive Agreement~~MANAGEMENT

OnItem ~~January 18, 2022, the Company, through its subsidiary, The Integrity Wellness Group, Inc~~5.,01 ~~(“Integrity~~Changes Wellness”) entered into a Joint Venture/Partnership Agreement (“Agreement”) with Medizone Bio, Inc., (“Medizone Bio”) of Richmond Hill, Ontario, Canada. The Agreement provides for a 50/50 partnership for the production of biodegradable face masks, and medical supplies, such as personal protective equipment (PPE) and COVID-19 testing materials. Under the Agreement, Integrity Wellness is to provide an initial funding of $300,000 in ~~financing~~Control ~~for Medizone Bio to manufacture the first Medizone Bio products purchase order. This purchase order has a value~~ of ~~$1,200,000~~Registrant. ~~The Company has borrowed the money for this purpose as described below.~~

~~Integrity~~On ~~Wellness~~August ~~will~~1, ~~provide~~2022, ~~the~~Regen ~~partnership with financing~~Biowellness, ~~marketing~~Inc., ~~sales~~the ~~distribution~~holder inof ~~wholesale~~4,400,000 ~~retail~~shares ~~and~~of ~~direct-to-consumer~~Series ~~(e,g., QVC,~~F ~~HSN,~~Preferred ~~Amazon,~~Voting ~~etc.)~~Stock, ~~financing~~entered ~~for~~into ~~general~~an ~~working~~asset ~~capital and~~ purchase agreement ~~order~~with ~~financing,~~Emergent ~~while~~Health ~~Medizone~~Corp. ~~Bio~~(“OTCPink ~~provides~~“EMGE”) for the ~~partnership with~~purchase aof ~~series~~all ofassets ~~purchase~~and ~~orders~~certain liabilities of Regen Biowellness. The ~~net profits~~4,400,000 ifshares ~~any,~~of ~~will~~Series beF ~~distributed~~Preferred ~~between~~Stock of the ~~partners~~Registrant inwhich ~~equal~~represents ~~proportions~~voting control over the Registrant.

~~Integrity~~Therefore, ~~Wellness~~as ~~has issued~~ a ~~Promissory~~result ~~Note~~of in the ~~principal~~asset ~~amount~~purchase ~~of $300~~agreement,~~000~~ tothere 7Xhas ~~Enterprises,~~been ~~Inc.~~a ~~(“7X”)~~change inof ~~exchange~~control ~~for 7X~~of ~~advancing~~the ~~$300,000~~Registrant. toEmergent ~~Integrity~~Health ~~Wellness~~Corp. ~~for~~is ~~the~~now ~~purchase order financing for~~ the ~~initial purchase order~~ holder of ~~Medizone~~the ~~Bio.~~Series ~~The~~F ~~Promissory Note~~Preferred ~~bears~~Stoc, ~~interest~~representing atvoting acontrol ~~rate~~ of ~~10% per annum and is due upon demand from~~ the ~~holder~~Registrant.

Item 95.~~01 Financial~~02 ~~Statements~~Departure ~~and~~of ~~Exhibits~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~(d)~~Effective ~~Exhibits~~as of August 15, 2022, the following individual was removed by a vote of the majority of shares entitled to vote as a Director of the Registrant.

Exhibit No.		Exhibit
10.1		Partnership Agreement between The Integrity Wellness Group, Inc. and Medizone Bio, Inc.
10.2		Promissory Note between The Integrity Wellness Group, Inc., and 7X Enterprises, Inc.

Name			Position
Dr. Babik Ghalili			Director

Effective as of August 15, 2022, the following resigned as an Officer of the Registrant.

Name			Position
Jim Morrison			President/CEO

Effective as of August 15, 2022, the following individual(s) were elected by a vote of the majority of shares entitled to vote to the positions indicated of the Registrant:

Name	Age		Position
Jim Morrison		63	Director
James W. Zimbler		58	Director and Interim President/CEO

Mr. Zimbler has served as the Registrant’s Vice President of Corporate Finance since November 2021, and prior was the President. He served as a director of the Company from since November 2017 to November 2021. Previously, from November 17, 2017, until July 1, 2020, he served as President of the Company in which role he was responsible for strategic decision making, capital expenditure planning and staffing matters. From December 2017 until June 2019, he served as President and a director of the predecessor iteration of a public company that is now Enzolytics, Inc., a drug development company. In December 2016 he founded Emerging Growth Advisors, Inc., a consulting firm providing advisory services related to mergers and acquisitions for corporations including the Company, and now Emerging Capital Strategies, Ltd., where he has served as President since formation. Prior to founding Emerging Growth Advisors, Inc., Mr. Zimbler served in a managerial role at other consulting firms, each specializing in mergers and acquisitions, roll ups and turn-around work.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.			Description
17.1			Letter of Resignation of Jim Morrison as President and CEO, dated August 15, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Cannagistics, Inc.
Date: January 25, 2022	By:	/s/ Jim Morrison
		Jim Morrison, President

Cannagistics, Inc.

3/s/ James W. Zimbler

James W. Zimbler

Interim President/Chief Executive Officer

Date: August 16, 2022

Filing Compare · Cannagistics Inc.